📰 Ioscience News
Page 15 - Ioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ioscience. Real-time updates on events, politics, business and more.
November 3, 2022
STOCKHOLM, SWEDEN / ACCESSWIRE / November 3, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates
November 3, 2022
Aston University researchers "feed" leftover coffee grounds to microalgae to produce low-emission biodiesel.
October 31, 2022
With effect from November 01, 2022, the unit rights in Sprint Bioscience AB will be traded on First North Premier Growth Market. Trading will continue up until and including November 10, 2022. Instrument:
October 27, 2022
VANCOUVER, BC / ACCESSWIRE / October 27, 2022 / EastWest Bioscience Inc. (the "Company" or "EastWest") (TSXV:EAST) announces the proposed issuance of 1,436,020 common shares at a price of CDN $0.05 per
October 20, 2022
DJ Holding(s) in Company Arix Bioscience PLC (ARIX) Holding(s) in Company 20-Oct-2022 / 16:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible
October 18, 2022
VALENCIA, CA / ACCESSWIRE / October 18, 2022 / Lief Labs, a premier formulation and product development innovator and manufacturer of dietary supplements, is pleased to announce that Lief's CEO & Founder
October 14, 2022
The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs)Its proprietary ADC technology opens the door
October 13, 2022
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland - October 13, 2022 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel
October 6, 2022
Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Corporation"), a drug discovery company aimed at developing therapeutics
September 30, 2022
Additional capital from Arrangement Agreement expected to fund Skye's Phase 1 and 2 clinical studies of proprietary synthetic cannabinoid-derivative therapeutic targeting glaucoma San Diego, California--(Newsfile